Sugi Predict

Sugi Predict / Compounds / SCHEMBL121809

SCHEMBL121809

SCHEMBL121809

O=C(O)c1cccc(-c2cccc(F)c2)c1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMO O15229 4/20 0.68
▸ RXRA P19793 2/20 0.59
▸ RXRB P28702 2/20 0.59
▸ DCLRE1B Q9H816 1/20 0.57
▸ CES2 O00748 1/20 0.55
▸ CES1 P23141 1/20 0.55
▸ MAP2K4 P45985 1/20 0.55
▸ ERN1 O75460 1/20 0.54
▸ KAT6A Q92794 1/20 0.54
▸ NR4A1 P22736 1/20 0.53
▸ NR4A2 P43354 1/20 0.53
▸ NR4A3 Q92570 1/20 0.53
▸ ESR1 P03372 1/20 0.52
▸ ESRRG P62508 1/20 0.52
▸ PARP1 P09874 1/20 0.52
▸ ESR2 Q92731 1/20 0.52
▸ KEAP1 Q14145 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29784144 0.90 KMO (0.66) KMORXRARXRBDCLRE1BMAP2K4
SCHEMBL3210250 0.90 KMO (0.60) KMORXRARXRBDCLRE1BERN1
SCHEMBL410738 0.90 KMO (0.66) KMORXRARXRBDCLRE1BMAP2K4
SCHEMBL2160048 0.89 KMO (0.53) KMORXRARXRBDCLRE1BCES2
SCHEMBL30189265 0.89 KMO (0.53) KMORXRARXRBDCLRE1BCES2
Biphenyl SCHEMBL2835937 0.88 KMO (0.68) KMORXRARXRBCES2CES1
SCHEMBL28396 0.87 CES2 (0.71) KMOCES2CES1NR4A2PARP1
SCHEMBL29665004 0.87 CES2 (0.71) KMOCES2CES1NR4A2PARP1
SCHEMBL13950378 0.87 CES2 (0.71) KMOCES2CES1NR4A2PARP1
SCHEMBL71238 0.87 KMO (0.86) KMORXRARXRBERN1KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026778-A1 GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR TIUMBIO CO., LTD. (KR) 2025-01-23 — — US disclosed
US-20240299559-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-12 — — US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
EP-4365181-A1 GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR TiumBio Co., Ltd. (KR) 2024-05-08 — — EP disclosed
WO-2023069700-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2023-04-27 — — WO disclosed
EP-4149945-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2023-03-22 — — EP disclosed
WO-2023277630-A1 GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR 주식회사 티움바이오 2023-01-05 — — WO disclosed
WO-2023277630-A1 GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR 주식회사 티움바이오 2023-01-05 — — WO disclosed
WO-2010124082-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 — — WO disclosed
WO-2010124112-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 — — WO disclosed
WO-2010124086-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 — — WO disclosed
WO-2010124116-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 — — WO disclosed
CN-1080257-C Guanidine derivatives as inhibitors of Na+/H+ exchange in cells FUJISAWA PHARMACEUTICAL CO (JP) 2002-03-06 — — CN disclosed
EP-0699185-B1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO (JP) 2001-09-05 — — EP disclosed
US-5824691-A CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-10-20 — — US disclosed
CN-1123545-A Guanidine derivatives as inhibitors of Na+/H+ exchange in cells FUJISAWA PHARMACEUTICAL CO (JP) 1996-05-29 — — CN disclosed
EP-0699185-A1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-03-06 — — EP disclosed
WO-1994026709-A1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 KMO 1511/4885RXRA 1972/4885RXRB 1765/4885
US-20240299559-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CDK2, SKP2, CDK1 KMO 2512/4885RXRA 3376/4885RXRB 3191/4885
US-20250026778-A1 GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR LGALS3, LGALS1, LGALS3BP KMO 3466/4885RXRA 2727/4885RXRB 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.